Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.10 USD
Change Today +0.214 / 2.71%
Volume 770.0
IMMY On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

imprimis pharmaceuticals inc (IMMY) Snapshot

Open
$7.85
Previous Close
$7.89
Day High
$8.10
Day Low
$7.85
52 Week High
10/24/14 - $9.24
52 Week Low
05/19/14 - $4.71
Market Cap
75.8M
Average Volume 10 Days
6.4K
EPS TTM
$-1.11
Shares Outstanding
9.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMPRIMIS PHARMACEUTICALS INC (IMMY)

Related News

No related news articles were found.

imprimis pharmaceuticals inc (IMMY) Related Businessweek News

No Related Businessweek News Found

imprimis pharmaceuticals inc (IMMY) Details

Imprimis Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing proprietary compounded drug therapies to physicians and patients in the United States. The company owns, markets, and sells a portfolio of proprietary combination formulations in ophthalmology and urology. Its ophthalmic formulations include anti-inflammatory and anti-bacterial combination formulations, such as Tri-Moxi, a compounded formulation that is a combination of triamcinolone acetonide and moxifloxacin hydrochloride used as an injection during ocular surgery, as well as an eye drop in pre-and post-ocular surgery; and Tri-Moxi-Vanc, a compounded formulation, which is a combination of triamcinolone acetonide, moxifloxacin hydrochloride, and vancomycin used as an injection during ocular surgery. The company’s ophthalmic formulations also comprise Pred-Moxi, a compounded formulation that is a combination of prednisolone and moxifloxacin hydrochloride used as an eye drop in pre-and post-ocular surgery. Imprimis Pharmaceuticals, Inc. markets its ophthalmic formulations under the Dropless Therapy and LessDrops brands. It also offers urology formulations, including heparin and alkalinized lidocaine, a patented urologic formulation, which is delivered directly to the bladder for the treatment of interstitial cystitis; and injectable pentoxifylline formulation for the treatment of certain fibrotic conditions, including Peyronie’s disease. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.

56 Employees
Last Reported Date: 03/12/15
Founded in 1998

imprimis pharmaceuticals inc (IMMY) Top Compensated Officers

Founder, Chief Executive Officer and Director
Total Annual Compensation: $327.5K
Chief Financial Officer
Total Annual Compensation: $154.1K
Compensation as of Fiscal Year 2014.

imprimis pharmaceuticals inc (IMMY) Key Developments

Imprimis Pharmaceuticals, Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Revenue Guidance for the First Quarter of 2015

Imprimis Pharmaceuticals, Inc. announced earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenue of $550,105 compared to $2,500 a year ago. Net loss was $2,745,280 or $0.30 per common share compared to $1,882,127 or $0.21 per common share a year ago. For the full year, the company reported total revenue of $1,660,246 compared to $10,000 a year ago. Net loss was $10,118,103 or $1.11 per common share compared to $7,643,124 or $0.88 per common share a year ago. The company used approximately $1.5 million in operating activities. The company expect to have sales variability in the first quarter of 2015 due to some seasonality effects, the company believe this positive market capture trend will continue. For 2015, the company expects that there will be a continued increase in revenue growth.

Imprimis Pharmaceuticals Seeks Acquisitions

Imprimis Pharmaceuticals, Inc. (NasdaqCM:IMMY) may pursue acquisitions of pharmacies or other strategic transactions that involve one-time expenditures. Imprimis also plan to pursue the development of additional proprietary compounded formulations in the ophthalmology, urology or other therapeutic areas, which may include continued activities to develop and commercialize current assets or, if and as opportunities arise, potential acquisitions of new intellectual property rights and assets.

Imprimis Pharmaceuticals, Inc. to Report Q4, 2014 Results on Mar 12, 2015

Imprimis Pharmaceuticals, Inc. announced that they will report Q4, 2014 results at 9:00 PM, GMT Standard Time on Mar 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMMY:US $8.10 USD +0.214

IMMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMMY.
View Industry Companies
 

Industry Analysis

IMMY

Industry Average

Valuation IMMY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 43.5x
Price/Book 9.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 39.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPRIMIS PHARMACEUTICALS INC, please visit www.imprimispharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.